BRAF and melanoma: In this study, resistant A375-NRASQ61K (mutant NRAS) and WM983B-BR (wild-type NRAS) melanoma cell lines were used, which harbor BRAFV600E, and exhibit resistance to BRAF inhibitor, Vemurafenib, compared to its parental cells.